News

We are now reaching out to our customers and partners with a new informative material – the LZVO Newsletter. From now on, we will offer the most important information on the activities of LZVO and the Latvian Medicines Verification System (LZVS) in a short and summarised form on a quarterly basis.

EMVO have issued the next EMVS Community Newsletter – March 2022. The Newsletter aims to inform about the Alert Management System, best practices on reducing alerts from the point of view of the Romanian NMVO.

European Commission (EC) has published a new version of the Questions & Answers document on “Safety Features for Medicinal Products for Human Use (V.19)”.

The European Commission has taken decision to extend the transitional period for a period of three years, which was determined in the context of the action of the medicine verification system regarding the medicine products exported to the United Kingdom* (UK) following its’ withdrew from the European Union.

Welcome to the “EMVS Community Holiday Bulletin 2021”, a collaboration between the European Medicines Verification Organisation (EMVO) and the National Medicines Verification Organisations (NMVOs).

EMVO informs, that prototype and first phase of development for AMS HUB has been completed. AMS HUB solution is currently under system test by provider (started at September 17). Next milestone would be production pilot phase – October 4.